HLD-0915 Drug Asset Due Diligence Report 2026

This HLD-0915 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1/2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether HLD-0915 can convert its Regulated induced proximity targeting chimeras (RIPTAC) profile and AR x BRD4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	HLD-0915 (query alias: HLD-0915)
Modality / target	Regulated induced proximity targeting chimeras (RIPTAC); AR x BRD4; AR degraders, BRD4 degraders
Highest global status	Phase 1/2
Originator	Halda Therapeutics LLC
Active developers	Halda Therapeutics OpCo, Inc., Halda Therapeutics LLC

The MCP disease footprint includes Metastatic castration-resistant prostate cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06800313	Phase 1/2	Recruiting	190	Frequency of dose-limiting toxicities (DLTs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Halda Therapeutics Announces First-in-Human Results for HLD-0915, an Oral RIPTAC™ Therapeutic Demonstrating Encouraging Safety and Anti-Tumor Activity in Metastatic Castration-Resistance Prostate Cancer (mCRPC)

Phase 1/2; n=31; evaluation: Positive. Reported fields: TRAE = TRAEs observed in ≥10% of patients were nausea in 6 (20%), anemia and fatigue, each in 3 (10%). ; TRAE = TRAEs observed in ≥10% of patients were nausea in 6 (20%), anemia and fatigue, each in 3 (10%). ; TRAE = TRAEs observed in ≥10% of patients were nausea in 6 (20%), anemia and fatigue, each in 3 (10%).

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

HLD-0915 addresses Metastatic castration-resistant prostate cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Regulated induced proximity targeting chimeras (RIPTAC)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-11-17	J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash	Phase 1/2	US$3,000.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO